A newly-formed Industry Vision Group (IVG) has brought together pharmaceutical and medical technology companies including Alcon, Alimera, Allergan, Bausch+Lomb, Bayer, Novartis and Spectrum Thea.
The group would focus on policy issues and securing greater prioritisation of eye health with policy makers and commissioners as well as striving to improve access to care, treatment and services for people with eye health conditions.
Richard Marsh, group chairman, said: ‘The IVG believes that the NHS should give even greater priority to eye care and it is never more important to make this case than at a time when all services are under pressure. We will work both together as companies, and with other organisations representing both patients and practitioners, to ensure that the NHS has a vision for vision that embraces all the potential that medicine and medical technology can bring.’